Systematic Review and Individual Patient Data Meta-Analysis Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Topotecan, Pegylated Liposomal Doxorubicin Hydrochloride
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (report contains no commercial in confidence data) Produced by Centre for Reviews and Dissemination, University of York Authors Ms Caroline Main, Research Fellow, Systematic Reviews, Centre for Reviews and Dissemination, University of York, YO10 5DD Ms Laura Ginnelly, Research Fellow, Health Economics, Centre for Health Economics, University of York, YO10 5DD Ms Susan Griffin, Research Fellow, Health Economics, Centre for Health Economics, University of York, YO10 5DD Dr Gill Norman, Research Fellow, Systematic Reviews, Centre for Reviews and Dissemination, University of York, YO10 5DD Mr Marco Barbieri, Research Fellow, Health Economics, The Economic and Health Research Centre, Universitat Pompeu Fabra, Barcelona, Spain Ms Lisa Mather, Information Officer, Centre for Reviews and Dissemination, University of York, YO10 5DD Dr Dan Stark, Senior Lecturer in Oncology and Honorary Consultant in Medical Oncology, Department of Oncology, Bradford Royal Infirmary Mr Stephen Palmer, Senior Research Fellow, Health Economics, Centre for Health Economics, University of York, YO10 5DD Dr Rob Riemsma, Reviews Manager, Systematic Reviews, Centre for Reviews and Dissemination, University of York, YO10 5DD Correspondence to Caroline Main, Centre for Reviews and Dissemination, University of York, YO10 5DD, Tel: (01904) 321055, Fax: (01904) 321041, E-mail: [email protected] Date completed September 2004 Expiry date September 2006 Contributions of authors Caroline Main Lead reviewer responsible for writing the protocol, study selection, data extraction, validity assessment and writing the final report. Laura Ginnelly Involved in the cost-effectiveness section, writing the protocol, study selection, data extraction, development of the economic model and report writing. -
ASHP Guidelines on Handling Hazardous Drugs
132 Drug Distribution and Control: Preparation and Handling–Guidelines ASHP Guidelines on Handling Hazardous Drugs ASHP published its first guidance on hazardous drugs (HDs) Because newer studies have shown that contamination in 1983 as part of the 1983–84 ASHP Practice Spotlight: Safe is widespread in healthcare settings and that more workers Handling of Cytotoxic Drugs.1,2 This was followed by tech- than previously thought are exposed, these guidelines should nical assistance bulletins in 1985 and 1990 and the ASHP be implemented wherever HDs are received, stored, pre- Guidelines on Handling Hazardous Drugs in 2006.3-5 The pared, transported, administered, or disposed.8-11 2006 guidelines were created to harmonize with the National Comprehensive reviews of the literature covering an- Institute for Occupational Safety and Health (NIOSH) Alert: ecdotal and case reports of surface contamination, worker ex- 6,9,12 Preventing Occupational Exposure to Antineoplastic and posure, and risk assessment are available from NIOSH, Other Hazardous Drugs in Health Care Settings issued in the Occupational Safety and Health Administration 13,14 15-20 2004.6 The ASHP 2006 HD guidelines were current to 2005. (OSHA), and individual authors. The primary goal In 2007, the United States Pharmacopeial Convention of this document is to provide recommendations for the safe revised United States Pharmacopeia (USP) chapter 797 handling of HDs. These guidelines represent the research (Pharmaceutical Compounding—Sterile Preparations)7 to and recommendations of many groups and individuals who harmonize with the NIOSH 2004 Alert. It became effective have worked tirelessly over decades to reduce the potential May 1, 2008, establishing many of the NIOSH recommenda harmful effects of HDs on healthcare workers. -
NOV 1 72010 1.0 Submitter
510(k) SUMMARY NOV 1 72010 1.0 Submitter Name Shen Wei (USA) Inc. Street Address 33278 Central Ave., Suite 102 Union City, CA. 94587 Phone No. (510)429-8692 Fax No. (510)487-5347 Date of Summary Prepared: 08/12/10 Prepared by: Albert Li 2.0 Name of the device: Glove Proprietary or Trade Name: Blue and Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs Common Name: Exam gloves Classification Name: Patient examination glove, Specialty Chemotherapy'(per 21 CFR 880.6250 product code LZC) Classification Information: Class I Nitrile patient examination glove 8OLZC, powder-free and meeting all the requirements of ASTM D 631 9-O0a-05 and is tested with chemotherapy drugs according to ASTM D 6978-05. 3.0 Identification of the Legally Marketed Device: Blue and Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera Regulatory Class I Nitrile patient examination Product code: 8OLZA 5 10(k): K092411 4.0 Description of the Device: Blue and Red with Pearlescent® Pigment, Powder Free Nitrite Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs meets all the requirements of ASTM D 6978-05, ASTM D63 19-00a(2005) and FDA 21 CFT 880.6250. 5.0 Intended Use of Device: Product: Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs A disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. This device is single use only. -
Chemotherapy Protocol
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL (7 day) Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel (7 day) Indication • Neoadjuvant / adjuvant therapy of early breast cancer • WHO Performance status 0, 1 Toxicity Drug Adverse Effect Cyclophosphamide Dysuria, haemorrhagic cystitis, taste disturbances Epirubicin Cardio-toxicity, urinary discolouration (red) Hypersensitivity, hypotension, bradycardia, peripheral Paclitaxel neuropathy, myalgia and back pain on administration The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Regimen • FBC, U&Es and LFTs prior to each cycle. • Ensure adequate cardiac function before starting treatment with epirubicin. Baseline LVEF should be measured, particularly in patients with a history of cardiac problems or in the elderly. Dose Modifications The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re- escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Please discuss all dose reductions / delays with the relevant consultant before prescribing if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Version 1.2 (November 2020) Page 1 of 7 Breast – Cyclophosphamide-Epirubicin-Paclitaxel (7 day) Haematological Prior to prescribing the following treatment criteria must be met on day one of treatment. Criteria Eligible Level Neutrophils equal to or more than 1x10 9/L Platelets equal to or more than 100x10 9/L Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL If counts on day one are below these criteria for neutrophils and platelets then delay treatment for seven days. -
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine -
(12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4. -
(12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al. -
Ep 2569287 B1
(19) TZZ _T (11) EP 2 569 287 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 413/04 (2006.01) C07D 239/46 (2006.01) 09.07.2014 Bulletin 2014/28 (86) International application number: (21) Application number: 11731562.2 PCT/US2011/036245 (22) Date of filing: 12.05.2011 (87) International publication number: WO 2011/143425 (17.11.2011 Gazette 2011/46) (54) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERBINDUNGEN ALS HEMMER DER ATR-KINASE COMPOSÉS UTILISABLES EN TANT QU’INHIBITEURS DE LA KINASE ATR (84) Designated Contracting States: • VIRANI, Aniza, Nizarali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abingdon GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oxfordshire OX144RY (GB) PL PT RO RS SE SI SK SM TR • REAPER, Philip, Michael Abingdon (30) Priority: 12.05.2010 US 333869 P Oxfordshire OX144RY (GB) (43) Date of publication of application: (74) Representative: Coles, Andrea Birgit et al 20.03.2013 Bulletin 2013/12 Kilburn & Strode LLP 20 Red Lion Street (73) Proprietor: Vertex Pharmaceuticals Inc. London WC1R 4PJ (GB) Boston, MA 02210 (US) (56) References cited: (72) Inventors: WO-A1-2010/054398 WO-A1-2010/071837 • CHARRIER, Jean-Damien Abingdon • C. A. HALL-JACKSON: "ATR is a caffeine- Oxfordshire OX144RY (GB) sensitive, DNA-activated protein kinase with a • DURRANT, Steven, John substrate specificity distinct from DNA-PK", Abingdon ONCOGENE, vol. 18, 1999, pages 6707-6713, Oxfordshire OX144RY (GB) XP002665425, cited in the application • KNEGTEL, Ronald, Marcellus Alphonsus Abingdon Oxfordshire OX144RY (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. -
BC Cancer Protocol Summary for Neoadjuvant Or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel
BC Cancer Protocol Summary for Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin, Cyclophosphamide and DOCEtaxel Protocol Code BRAJFECD Tumour Group Breast Contact Physician Dr. Stephen Chia ELIGIBILITY: . Node positive (any T, N1-3) or high risk, node negative early stage breast cancer . Less than or equal to 65 years of age or fit patients greater than 65 years deemed appropriate by supervising physician . ECOG 0-1 . HER-2 negative . Adequate renal and hepatic function . Adequate cardiac function EXCLUSIONS: . ECOG 2-4 . Significant hepatic dysfunction . Congestive heart failure (LVEF less than 45%) or other significant heart disease . Greater than or equal to grade 2 sensory or motor neuropathy . Pregnancy or lactation . Unsuitable for aggressive adjuvant chemotherapy TESTS: . Baseline: CBC & diff, platelets, creatinine, bilirubin, ALT, Alk Phos, LDH, GGT . Before each treatment (Day 1): CBC & diff, platelets. Prior to Cycle #4: CBC & diff, platelets, bilirubin, ALT, Alk Phos (see Precaution #5 for guidelines regarding hepatic dysfunction and DOCEtaxel). If clinically indicated: bilirubin, ALT, Alk Phos, creatinine, protein level, albumin, GGT, LDH, urea, MUGA scan or echocardiogram PREMEDICATIONS: . For the 3 cycles of epirubicin, fluorouracil and cyclophosphamide, antiemetic protocol for highly emetogenic chemotherapy (see protocol SCNAUSEA) . For the 3 cycles of DOCEtaxel: Dexamethasone 8 mg PO bid for 3 days, starting one day prior to each DOCEtaxel administration. Patient must receive minimum of 3 doses pre-treatment. Additional antiemetics not usually required. DOCEtaxel-induced onycholysis and cutaneous toxicity of the hands may be prevented by wearing frozen gloves starting 15 minutes before DOCEtaxel infusion until 15 minutes after end of DOCEtaxel infusion; gloves should be changed after 45 minutes of wearing to ensure they remain cold during the entire DOCEtaxel infusion. -
In Advanced Upper Tract Urothelial Carcinoma
ANTICANCER RESEARCH 37 : 1875-1883 (2017) doi:10.21873/anticanres.11525 Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma SHENG-CHUN HUNG 1, SHIAN-SHIANG WANG 1,2,3 , CHUN-KUANG YANG 1, JIAN-RI LI 1, CHEN-LI CHENG 1, YEN-CHUAN OU 1, HAO-CHUNG HO 1, KUN-YUAN CHIU 1 and CHUAN-SHU CHEN 1 1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.; 2School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.; 3Department of Applied Chemistry, National Chi Nan University, Puli, Taiwan, R.O.C. Abstract. Aim: To evaluate the efficacy of methotrexate, (3). Its behavior appears multi-focal and in 17% of cases, epirubicin and cisplatin (MEC) or gemcitabine and cisplatin concurrent bladder cancer is present (4). Furthermore, an (GC) as adjuvant chemotherapy in advanced upper tract estimated 22-47% of patients with UTUC may suffer from urothelium carcinoma (UTUC). Patients and Methods: From bladder recurrence (5) and 2-6% of patients suffer from 2002 January to 2008 December, a total of 70 patients with contralateral recurrence (6). advanced UTUC received radical nephroureterctomy at our A radical nephroureterectomy and bladder cuff excision is Institute with MEC and GC as adjuvant chemotherapy. Disease- standard treatment for UTUC, while offering the benefits of free survival (DFS), cancer-specific survival (CSS) and overall preventing tumor spreading and an entire urinary tract resection survival (OS) among the two groups were evaluated. Results: (7). However, after definite and en bloc surgical removal of the The MEC (n=30) and GC group (n=40) were compared and kidney, it still appears to be a poor prognosis for advanced showed no significant differences in DFS (p=0.859), CSS disease, with a <50% 5-year cancer-specific survival rate in (p=0.722) and OS (p=0.691). -
Natural Products. a History of Success and Continuing Promise for Drug Discovery and Development
Natural Products. A History of Success and Continuing Promise for Drug Discovery and Development Gordon M. Cragg NIH Special Volunteer [email protected] David J. Newman Natural Products Branch Developmental Therapeutics Program National Cancer Institute EARLY DOCUMENTATION OF USE OF MEDICINAL PLANTS http://www.nlm.nih.gov/hmd/collections/archives/index.html • Mesopotamian ~2,600 B. C. E. • Egyptian ~ 1,800 B. C. E. • Chinese – ~1,100 B. C. E. and continuing • Indian ~ 1,000 B. C. E. and continuing • Greek ~ 500 B. C. E. Greco-Roman expertise preserved and coordinated with other traditions by Islamic cultures during the Dark Ages ~ 400-1,100 CE Avicenna. Persian pharmacist, physician, poet, philosopher author: canon medicinae – “final codification of Greco-Roman medicine” Great Moments in Pharmacy Collection APhA Traditional Medicine and Drug Discovery • 80% of the world population resides in developing countries • 80% of people in developing countries utilize plants to meet their primary health care needs • Global pop. ca. 7 billion ca. 4.5 billion people utilize plants to meet their primary health care needs Farnsworth NR, et al. Medicinal Plants in Therapy. Bull. W.H.O. 63:965-981 (1985) Fabricant and Farnsworth, EnViron. Health Perspect. 109, 69-75 (2001) Cordell and Clovard, J. Nat. Prod., 75, 514-525 (2012) Norman Farnsworth 1800s. Discovery of some active principles of major herbal preparations Newman and Cragg. Natural Product Chemistry for Drug Discovery, eds. Buss and Butler, M. S., Royal Soc. Chem., Cambridge, 2010, pp. 3-27 European chemists (apothecaries) revolutionized drug discovery and development. 1817. Sertϋrner reports isolation of morphine from Papaver somniferum. -
Breast Pathway Group – FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Advanced Breast Cancer
Breast Pathway Group – FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Advanced Breast Cancer Indication: First line palliative therapy in selected patients with advanced breast cancer Regimen details: Fluorouracil 600mg/m2 IV Day 1 Epirubicin *75mg/m2 IV Day 1 Cyclophosphamide 600mg/m2 IV Day 1 * Consider using FEC60 regimen in patients > 60 years Administration: Epirubicin IV bolus injection via a fast-running Sodium Chloride 0.9% infusion Fluorouracil IV bolus injection via a fast-running Sodium Chloride 0.9% infusion Cyclophosphamide may be administered as IV bolus injection via a fast-running Sodium Chloride 0.9% infusion or as a short infusion e.g. in 100-250ml Sodium Chloride 0.9% over 30 minutes Frequency: Day 1, every 21 days, for 6 cycles Pre-medication: Not routinely required Anti- emetics: Highly Emetogenic Follow local anti-emetic policy. Supportive medication: Mouthcare as per local policy. Extravasation: Fluorouracil: Irritant Epirubicin: Vesicant Cyclophosphamide: Non-vesicant Epirubicin should be administered with appropriate precautions to prevent extravasation. If there is any possibility that extravasation Version: 1.0 Supersedes: all other versions Approved by LCA Breast Pathway Chemotherapy Lead: Mark Harries November 2014 Reason for Update: LCA Protocol Approved by LCA Joint Delivery Subgroup Co-Chairs: Pauline McCalla & Rebecca Johl Development Prepared by: Anabel Rodriguez Marina Approved by LCA Medicines & Chemotherapy Steering Group Chair: Jamie Ferguson Second check by: Lisa Yuen Date prepared: November 2014 Review Date: November 2016 Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA).